Pharmafile Logo
Pharmafocus logo
Advanced Search

Hepatology

Showing 15 posts of 15 posts found.

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025
Manufacturing and Production Hepatology, Norgine, Vir Biotechnology

Norgine has announced its exclusive licensing agreement with Vir Biotechnology, under which Norgine will commercialise the combination of tobevibart and …

News

Combination treatments: Takeda’s Implementation Framework and the broader landscape

September 23, 2025
Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …

Feature
hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

August 22, 2025
Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …

News

Global study calls for overhaul of hepatitis B care to meet WHO targets

August 21, 2025
Medical Communications, Medical/ Scientific Writing Hepatology, World Health Organisation, hepatitis B, liver damage, medical study

A major global study has warned that current models of hepatitis B care are failing patients and could jeopardise the …

News

Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development

June 30, 2025
Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics

Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …

Appointment

FDA approves drug for primary biliary cholangitis

August 15, 2024
Research and Development FDA Approval, FDA approva;, Hepatology, liver, primary biliary cholangitis

Accelerated approval has been granted for Gilead Science’s Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) by the US Food …

News

Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial

July 26, 2024
Research and Development Calliditas, Hepatology, clinical trials, elevated liver stiffness, primary biliary cholangitis

 Calliditas Therapeutics AB today announced that the phase 2b TRANSFORM trial met its primary endpoint. The trial showed statistically significant …

News

First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment

June 19, 2024
Research and Development Assembly Biosciences, Hepatology, clinical trial, hepatitis

Assembly Biosciences has announced that the first participant has been dosed in its phase 1b trial of ABI-4334, the company’s …

News

Eli Lilly shares results for tirzepatide for MASH resolution

June 10, 2024
Research and Development Eli Lilly, Hepatology, MASH, clinical trial, liver

Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, with or without type 2 …

News

Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis

June 5, 2024
Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar

Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …

News

Mirum Pharmaceuticals publishes phase 3 MARCH maralixibat data in The Lancet

May 8, 2024
Research and Development Hepatology, Mirum Pharmaceuticals, PFIC, The Lancet, clinical trials

Biopharma company Mirum Pharmaceuticals has announced data from its phase 3 MARCH-PFIC study which evaluated maralixibat in patients with progressive …

News

Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment

February 26, 2024
Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide

Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …

News

GSK gains FDA Fast Track designation for chronic hepatitis B treatment

February 12, 2024
Medical Communications FDA, GSK, Hepatology, fast track designation, hepatitis B

GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational …

News

Bit.bio announces cell therapy pipeline

November 8, 2023
Medical Communications Hepatology, bit.bio, cell therapy, liver failure

Bit.bio has announced its cell therapy pipeline as well as having shared its lead cell therapy candidate, preparing to enter …

News

Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients

June 8, 2023
Medical Education Echosens, Hepatology, Inventiva, liver disease, nash, non-alcoholic steatohepatitis

French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens to bring attention to, and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025